On August 5, Charles River Laboratories rose 8.06% in pre-market trading, trading at $254.73/share, with Turnover of $5,011.2.

The surge was driven by the company's Q2 earnings release, which significantly exceeded market expectations on all key metrics. Adjusted EPS came in at $3.02, beating the consensus estimate of $2.74 by approximately 10.2%. Revenue reached $1.004 billion, surpassing the $975.7 million estimate. Notably, the market had previously anticipated a modest year-over-year revenue decline for the quarter.

Simultaneously, management raised full-year adjusted EPS guidance to a range of $11.15–$11.45, up from the prior $10.80–$11.30 range and above the FactSet consensus of $11.11. This marks the second guidance increase this year, following a prior revision in February tied to planned divestitures. The strong results build on Q1 momentum, where the company also beat estimates, and validate analyst expectations from RBC and Morgan Stanley that Charles River was positioned to outperform in the second half of the year amid improving biopharma funding conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)